Data Sheet (Cat.No.T77018)

TargetMol

Garadacimab

Product Details

Target:	Factor Xa
Reactivity:	Human
Conjugation:	Unconjugated
Molecular Weight:	146.5 kDa (Predicted)
CAS No.	2162134-62-3

Applications

Application:	ELISA, FCM, Functional assay

Properties

Formulation:	Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin:	<1.0 EU/mg
Stability & Storage:	Store at low temperature -20°C for 1 year Actual storage temperature shall be subject to the COA.
Shipping:	Shipping with blue ice/Shipping at ambient temperature.

Biological Description

Description:	Garadacimab (CSL312) is a potent whole-human IgG4 monoclonal antibody targeting activation factor XII (FXIIa). Garadacimab can be used to study hereditary angioedema.
In vitro:	Garadacimab (CSL312) demonstrates high affinity to activated βFXIIa with a KD of 140 pM. In an activated partial thromboplastin time (aPTT) assay with human plasma, Garadacimab exhibits potency. Notably, it displays high selectivity over a panel of relevant human serine proteases, including FVIIa, FIXa, FXa, FXIa, kallikrein, tissue plasminogen activator, activated protein C, and urokinase plasminogen activator[2].
In vivo:	In male and female cynomolgus monkeys, Garadacimab (0.5, 1, and 3 mg/kg i.v. and 6 and 20 mg/kg s.c. over 8 weeks) shows a dose-dependent increase in plasma concentrations[1]. Garadacimab exhibits an inhibitory effect on FXII-mediated kallikrein activity. Moreover, it induces a clear dose-dependent prolongation of activated partial thromboplastin time (aPTT) with no associated effect on the prothrombin time[1].

References

Dipti Pawaskar, et al. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312). Clin Transl Sci. 2022 Mar;15(3):709-720.
Helen Cao, et al. Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation. J Allergy Clin Immunol. 2018 Oct;142(4):1355-1358.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481